Respiratory syncytial virus having cleavage-resistant G protein and related materials and methods

US10758607B2 · kind B2 · utility

Assignee

• Research Institute at Nationwide Children's Hospital · US

Inventors

• Mark E. Peeples · Bexley, US
• Steven A. Kwilas · Fort Detrick, US
• Jacqueline Dianne Corry · Columbus, US

Key dates

• Filing date: Jun 17, 2016
• Grant date: Sep 1, 2020
• Expiry date: Jun 17, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18534
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments disclosed herein provide compositions, methods, and uses for respiratory syncytial viruses (RSV) and immunogenic compositions thereof. Certain embodiments provide RSV having cleavage-resistant mutated attachment (G) glycoproteins. In some embodiments, the cleavage-resistant G protein mutants increase production of live attenuated RSV in host cells. Also provided are methods for amplifying RSV in host cells, wherein the amplified RSV has full length G protein. In certain embodiments, the amplified RSV having full length G protein is formulated into immunogenic compositions, including vaccines. Other embodiments provide methods for inducing an effective immune response against RSV infection in a subject.